摘要
靶向治疗是目前晚期肝癌的常规治疗手段之一,免疫治疗的出现使晚期肝癌的治疗进入新时代,2个治疗手段具有协同促进作用,联合使用可使部分晚期肝癌患者获益。以介入为主的局部治疗,能够迅速控制肿瘤进展,促进肿瘤抗原的表达、释放,在此基础上联合免疫+靶向的全身治疗,可使部分患者延长生存时间甚至获得治愈机会。笔者报道1例介入治疗基础上联合免疫+抗血管生成靶向药物一线治疗晚期肝癌患者的诊断与治疗经验。其研究结果显示:患者达到病理学完全缓解,成功转化后行手术切除。患者预后良好,生命质量较高。
Targeted therapy is one of the conventional treatments for advanced hepato-cellular carcinoma(HCC).In recent years,immunotherapy has created a new era of HCC treatment.The combination of targeted therapy and immunotherapy has synergistic effects,which taking survival benefits to patients with advanced HCC.Local therapy,represented by interventional treatment,can rapidly control the development of tumor and promote the expression and releasing of tumor antigen.On the basis of local therapy and combination of immunotherapy plus targeted therapy,it can offer the possibility to prolong the survival of patients,and even obtain the chance of cure.The authors introduce the diagnosis and treatment of an advanced HCC patient with inter-ventional treatment combined with immunotherapy plus anti-angiogenesis targeted therapy.Results show that patient achieving pathological complete response and undergoing resection after conver-sion therapy.The patient has a good prognosis with a better quality of live.
作者
袁泽南
蔡建业
李海波
余振宇
朱曙光
张剑文
Yuan Zenan;Cai Jianye;Li Haibo;Yu Zhenyu;Zhu Shuguang;Zhang Jianwen(Department of Hepatic Surgery&Liver Transplantation,the Third Affiliated Hospital,Sun Yat-sen University,Guangzhou 510630,China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2022年第S01期15-19,共5页
Chinese Journal of Digestive Surgery
基金
广东省自然科学基金资助项目(2018A030313108)。
关键词
肝肿瘤
晚期
免疫治疗
联合治疗
转化治疗
Liver neoplasms
Advanced
Immunotherapy
Combined therapy
Conver-sion therapy
